Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma

Journal of Neuro-Oncology

Volumn 27, Issue 2, 1996, Pages 149-155

  Fulton, Dorcas ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

Chemotherapy; Etoposide; Malignant glioma; VP16

Indexed keywords

CARMUSTINE; ETOPOSIDE; LOMUSTINE; NITROSOUREA; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN TUMOR; CELL CYCLE; CELL DIVISION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; LEUKOCYTE COUNT; MALE; NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; THROMBOCYTE COUNT; TUMOR GROWTH;

EID: 0030053959     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00177478     Document Type: Article

References (17)

1. Stewart DJ, Richard MT, Hugenholtz H, Dennery JM, Belanger R, Gerin-Lajoie J, Montpetit V, Nundy D, Prior J, Hopkins HS: Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neuro-Oncol 2: 133-139,1984
2. Tirelli U, D'Incaci M, Canetta R, Tumolo S, Franchin G, Veronesi A, Galligioni E, Trovo MG, Rossi C, Grigoletto E: Etoposide (VP-16-213) in malignant brain tumors: A phase II study. J Clin Oncol 2: 432-437,1984
3. Feun LG, Lee YY, Yung WKA, Savaraj N, Wallace S: Intracarotid VP-16 in malignant brain tumors. J Neuro-Oncol 4: 397-401,1987
4. Radice PA, Bunn PA Jr, Ihde DC: Therapeutic trial with VP-16-213 and VM-26: Active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Cancer Treat Rep 63: 1231-1239,1979
5. Rosenczweig M, Von Hoff DD, Henney JE, Muggia FM: VM-26 and VP-16: a comparative analysis. Cancer 40: 334-342,1977
6. Gerosa MA, DiStefano E, Olivi A: VM-26 monochemotherapy trial in the treatment of recurrent supratentorial gliomas: preliminary report. Surgical Neurology 15: 128-134, 1981
7. Kessinger A, Lemon HM, Foley JF: VM-26 as a second drug in the treatment of brain gliomas. Cancer Treat Rep 63: 511-512,1979
8. Sklansky BD, Mann-Kaplan RS, Reynolds AF Jr, Rosenblum ML, Walker MD: 4"-demethyl-epipodophyllotoxinB-D-Trenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms. Cancer 33: 460-467,1974
9. Hoshino T, Wilson CB: Cell kinetic analyses of human malignant brain tumor (gliomas). Cancer 44: 956-962,1979
10. Morimura T, Kitz K, Budka H: In situ analysis of cell kinetics in human brain tumors. Acta Neuropathol 77: 276-282,1989
11. Raghavan R, Steart PV, Weller RO: Cell proliferation patterns in the diagnosis of anaplastic astrocytomas and glioblastoma multiforme: a ki-67 study. Neuropathol Appl Neurobiol 16: 123-133,1990
12. Greco FZ, Johnson DH, Hainsworth JD: Chronic oral etoposide. Cancer 67: 303-309,1991
13. Greco FA: Future directions for etoposide therapy. Cancer 67 (1 Suppl): 315-318,1991
14. Aisner J, Lee EJ: Etoposide. Current and future status. Cancer 67 (1 Suppl): 215-219,1991
15. Chamberlain MC: Recurrent brainstem gliomas treated with oral VP-16. J Neuro-Oncology 15: 133-139,1993
16. Minami H, Ando Y, Sakai S, Shimokata K: Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol 13: 191-199,1995
17. Kiya K, Uozimi T, Ogasawara H, Sugiyama K, Hotta T, Mikami T, Kurisu K: Penetration of etoposide into human ma-lignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol 29: 339-342,1992